Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
▲ nikotinsyra (depotpreparat 1 000 mg till 2 000 mg vid vecka 5)
▲nicotinic acid (prolonged-release 1000 mg to 2000 mg at week 5)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
kön har ingen kliniskt betydelsefull påverkan på farmakokinetiken för nikotinsyra (depotpreparat).
gender has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged-release formulation).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
de patienter som byter från 2 000 mg eller en högre dos av depotpreparat med nikotinsyra kan inleda behandling med tredaptive med dosen 2 000 mg/40 mg.
those patients switching from 2,000 mg or more of prolonged-release nicotinic acid can initiate tredaptive at the 2,000 mg/40 mg dose.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
hos patienter som behandlades med nikotinsyra (depotpreparat) förblev frekvensen flush konstant (efter vecka 6).
in patients continuing in the first study (24 weeks), the frequency of moderate or greater flushing in patients treated with pelzont declined and approached that of patients receiving placebo (see figure 1), whereas in patients treated with nicotinic acid (prolonged-release formulation) the flushing frequency remained constant (after week 6).
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Ålder har ingen kliniskt betydelsefull påverkan på farmakokinetiken för nikotinsyra (depotpreparat) baserat på en sammanslagen analys av patienter i åldern 18-65 år.
age has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged-release formulation) based on a composite analysis of subjects ages 18-65 years.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
patienter som byter från en lägre dos än 2 000 mg av depotpreparat med nikotinsyra bör inleda behandlingen med startdosen 1 000 mg/ 20 mg och efter 4 veckor dosjusteras upp till underhållsdosen 2 000 mg/ 40 mg.
patients switching from less than 2000 mg of prolonged-release nicotinic acid should initiate therapy at the starting dose of 1000 mg/ 20 mg and advance to the 2000 mg/ 40 mg maintenance dose after four weeks.
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
etniskt ursprung har ingen kliniskt betydelsefull påverkan på farmakokinetiken för nikotinsyra (depotpreparat) baserat på farmakokinetikdata inkluderande latinamerikanska, vita, svarta och inhemska amerikanska etniska grupper.
race has no clinically meaningful effect on the pharmacokinetics of nicotinic acid (prolonged-release formulation) based on pharmacokinetic data including subjects of hispanic, white, black, and native american racial groups.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
i dessa studier var procentandelen patienter som behandlades med trevaclyn, nikotinsyra eller placebo/simvastatin som avbröt behandlingen på grund av flushrelaterade symtom (dvs rodnad, värmekänsla, klåda och/eller stickningar) 7,2%, 16,6% respektive 0,4% (analys gjord genom sammanslagning av depotpreparat med nikotinsyra respektive placebo/simvastatin).
in these studies, the percentage of patients taking trevaclyn, nicotinic acid (pooled prolonged-release formulations) or pooled placebo/simvastatin who discontinued due to any flushing-related symptom (redness, warmth, itching and tingling) was 7.2 %, 16.6 %, and 0.4 %, respectively.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: